慢性乙型肝炎病毒感染者肝细胞癌筛查和监测

doi:10.3969/j.issn.1672-5069.2021.06.004

摘要/Abstract

摘要： 肝细胞癌是我国常见恶性肿瘤,疾病负担十分沉重。筛查和监测是提高肝细胞癌患者早诊早治和生存率的有效措施。慢性乙型肝炎病毒感染是我国肝细胞癌的主要病因,有必要制定专门的筛查和监测策略。中国肝炎防治基金会组织国内有关专家,参考国内外相关指南,并结合当前研究进展和临床实践经验共同讨论后达成一致意见,旨在为规范开展慢性乙型肝炎病毒感染者肝细胞癌的筛查和监测提供参考,进而改善我国肝细胞癌的防控效果和患者预后。

关键词: 乙型肝炎病毒, 肝细胞癌, 筛查, 监测

Abstract: Hepatocellular carcinoma is a common malignant tumor with a very heavy disease burden in China. Screening and surveillance are effective measures to improve the early diagnosis and treatment and survival rate of patients with hepatocellular carcinoma. Chronic hepatitis B virus infection is the main cause of hepatocellular carcinoma, so it is necessary to formulate special screening and surveillance strategies in China. The Chinese Foundation for Hepatitis Prevention and Control organized relevant domestic experts to review domestic and foreign guidelines, combined with current research progress and clinical practice experience, to form a review, with aim to provide standard reference and improve preventive control and outcome effectiveness for HCC screening and surveillance in patients with chronic HBV infection.

Key words: Hepatitis B virus, Hepatocellular carcinoma, Screening, Surveillance

中国肝炎防治基金会肝细胞癌筛查和监测项目专家组. 慢性乙型肝炎病毒感染者肝细胞癌筛查和监测[J]. 实用肝脏病杂志, 2021, 24(6): 776-785.

Expert Group for Project of Hepatocellular Carcinoma Screening and Surveillance, Chinese Foundation for Hepatitis Prevention and Control. Screening and surveillance for hepatocellular carcinoma in patients with chronic hepatitis B virus infection[J]. Journal of Practical Hepatology, 2021, 24(6): 776-785.

参考文献

[1] Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005[J]. J Clin Oncol, 2009, 27(9): 1485-1491. DOI: 10.1200/JCO.2008.20.7753.
[2] GLOBOCAN 2020[Z]. http: //gco.iarc.fr/today.
[3] Wang MJ, Wang YT, Feng XS, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese National Cancer Center[J]. Int J Infect Dis, 2017, 65: 15-21. DOI: 10.1016/j.ijid.2017.09.003.
[4] Chayanupatkul M, Omino R, Mittal S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection[J]. J Hepatol, 2017, 66(2): 355-362. DOI: 10.1016/j.jhep.2016.09.013.
[5] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华肝脏病杂志, 2020, 28 (2): 112-128. DOI: 10.3760/cma.j.issn.1007-3418.2020.02.004.
[6] 中国抗癌协会原发性肝癌患者指南编写专家委员会. 中国抗癌协会原发性肝癌患者指南[Z]. https: //mp.weixin.qq.com/s/hFeTpjqk7tJy1LOqz6Lq9A.
[7] 中国临床肿瘤学会. CSCO原发性肝癌诊疗指南(2020)[M]. 北京; 人民卫生出版社. 2020: 1-131.
[8] 中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国研究型医院学会肝病专业委员会, 中华医学会肝病学分会, 等. 原发性肝癌的分层筛查与监测指南(2020版)[J]. 中华肝脏病杂志, 2021, 29(1): 25-40. DOI: 10.3760/cma.j.cn112152-20201109-00970.
[9] 中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版)[J]. 中华肝脏病杂志, 2021, 29(3): 216-226. DOI: 10.3760/cma.j.cn501113-20210210-00082.
[10] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): 161-184. DOI: 10.3969/j.issn.1672-5069.2020.01.044.
[11] Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma 2018 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2018, 68(2): 723-750. DOI: 10.1002/hep.29913.
[12] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370. DOI: 10.1007/s12072-017-9799-9.
[13] European Association for the Study of the Liver.EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
[14] Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv238-iv255. DOI: 10.1093/annonc/mdy308.
[15] Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2017 (4th JSH-HCC guidelines) 2019 update[J]. Hepatol Res, 2019, 49(10): 1109-1113. DOI: 10.1111/hepr.13411.
[16] El-Serag HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J]. Gastroenterology, 2012, 142(6): 1264-1273. DOI: 10.1053/j.gastro.2011.12.061.
[17] Fattovich G, Bortolotti F, Donato F.Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48(2): 335-352. DOI: 10.1016/j.jhep.2007.11.011.
[18] ORGANIZATION T W H. Publications/overview/Interim guidance for country validation of viral hepatitis elimination (June 2021)[Z]. https: //www.vhpb.org/node/267.
[19] Liu J, Liang WN, Jing WZ, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
[20] Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma[J]. N Engl J Med, 2002, 347(3): 168-174. DOI: 10.1056/NEJMoa013215.
[21] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.
[22] Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death[J]. Gastroenterology, 2010, 138(5): 1747-1754. DOI: 10.1053/j.gastro.2010.01.042.
[23] Shi Y, Wu YH, Wu W, et al. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis[J]. Liver Int, 2012, 32(2): 231-240. DOI: 10.1111/j.1478-3231.2011.02481.x.
[24] Ching LK, Gounder PP, Bulkow L, et al. Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people[J]. Liver Int, 2016, 36(10): 1507-1515. DOI: 10.1111/liv.13129.
[25] Haga H, Saito T, Okumoto K, et al. Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus is equivalent between genotype B and C in long term[J]. J Viral Hepat, 2019, 26(7): 866-872. DOI: 10.1111/jvh.13099.
[26] Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma[J]. J Natl Cancer Inst, 2008, 100(16): 1134-1143. DOI: 10.1093/jnci/djn243.
[27] Kamal H, Fornes R, Simin J, et al. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies[J]. J Viral Hepat, 2021, 28(10): 1431-1442. DOI: 10.1111/jvh.13577.
[28] Li KW, Kramvis A, Liang SJ, et al. Higher prevalence of cancer related mutations 1762T/1764A and PreS deletions in hepatitis B virus (HBV) isolated from HBV/HIV co-infected compared to HBV-mono-infected Chinese adults[J]. Virus Res, 2017, 227: 88-95. DOI: 10.1016/j.virusres.2016.10.002.
[29] Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15): 1521-1531. DOI: 10.1056/NEJMoa033364.
[30] Lok AS, Perrillo R, Lalama CM, et al. Low incidence of adverse outcomes in adults with chronic hepatitis B virus infection in the era of antiviral therapy[J]. Hepatology, 2021, 73(6): 2124-2140. DOI: 10.1002/hep.31554.
[31] Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2011, 9(1): 64-70. DOI: 10.1016/j.cgh.2010.08.019.
[32] Yu MW, Chang HC, Liaw YF, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives[J]. J Natl Cancer Inst, 2000, 92(14): 1159-1164. DOI: 10.1093/jnci/92.14.1159.
[33] Tan YF, Zhang XY, Zhang W, et al. The influence of metabolic syndrome on the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection in mainland China[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(12): 2038-2046. DOI: 10.1158/1055-9965.EPI-19-0303.
[34] Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14(6): 889-919. DOI: 10.1007/s12072-020-10094-2.
[35] Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China[J]. Cancer Epidemiol Biomarkers Prev, 1994, 3(1): 3-10.
[36] Lee YCA, Cohet C, Yang YC, et al. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer[J]. Int J Epidemiol, 2009, 38(6): 1497-1511. DOI: 10.1093/ije/dyp280.
[37] Lin CW, Lin CC, Mo LR, et al. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis[J]. J Hepatol, 2013, 58(4): 730-735. DOI: 10.1016/j.jhep.2012.11.045.
[38] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. DOI: 10.1016/S0140-6736(17)33326-3.
[39] Park JW, Chen MS, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35(9): 2155-2166. DOI: 10.1111/liv.12818.
[40] Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus[J]. Hepatology, 1990, 12(4 Pt 1): 671-675. DOI: 10.1002/hep.1840120409.
[41] McMahon BJ. Epidemiology and natural history of hepatitis B[J]. Semin Liver Dis, 2005, 25 Suppl 1: 3-8.
[42] Bialecki ES, Di Bisceglie AM. Clinical presentation and natural course of hepatocellular carcinoma[J]. Eur J Gastroenterol Hepatol, 2005, 17(5): 485-489. DOI: 10.1097/00042737-200505000-00003.
[43] Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival[J]. Hepatology, 1992, 16(1): 132-137. DOI: 10.1002/hep.1840160122.
[44] Okuda H, Obata H, Motoike Y, et al. Clinicopathological features of hepatocellular carcinoma--comparison of hepatitis B seropositive and seronegative patients[J]. Hepatogastroenterology, 1984, 31(2): 64-68.
[45] Shijo H, Okazaki M, Koganemaru F, et al. Influence of hepatitis B virus infection and age on mode of growth of hepatocellular carcinoma[J]. Cancer, 1991, 67(10): 2626-2632. DOI: 10.1002/1097-0142(19910515)67: 10<2626: aid-cncr2820671038> 3.0.co;2-4.
[46] An C, Choi YA, Choi D, et al. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease[J]. Clin Mol Hepatol, 2015, 21(3): 279-286. DOI: 10.3350/cmh.2015. 21.3.279.
[47] Ebara M, Ohto M, Shinagawa T, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. a study in 22 patients[J]. Gastroenterology, 1986, 90(2): 289-298. DOI: 10.1016/0016-5085(86)90923-6.
[48] Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004, 130(7): 417-422. DOI: 10.1007/s00432-004-0552-0.
[49] Brar G, Greten TF, Graubard BI, et al. Hepatocellular carcinoma survival by etiology: a SEER-medicare database analysis[J]. Hepatol Commun, 2020, 4(10): 1541-1551. DOI: 10.1002/hep4.1564.
[50] Su F, Weiss NS, Beste LA, et al. Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B[J]. J Hepatol, 2021, 74(4): 850-859. DOI: 10.1016/j.jhep.2020.11.023.
[51] 全国多中心前瞻性肝癌极早期预警筛查项目(PreCar)专家组. 中国肝癌早筛策略专家共识[J]. 中华肝脏病杂志, 2021, 29(6) : 515-522. DOI: 10.3760/cma.j.cn501113-20210605-00264.
[52] Loomba R, Lim JK, Patton H, et al. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review[J]. Gastroenterology, 2020, 158(6): 1822-1830. DOI: 10.1053/j.gastro.2019.12.053.
[53] Erkan B, Meier J, Clark TJ, et al. Non-invasive diagnostic criteria of hepatocellular carcinoma: comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC[J]. PLoS One, 2019, 14(12): e0226291. DOI: 10.1371/journal. pone.0226291.
[54] Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis[J]. Gastroenterology, 2018, 154(6): 1706-1718.e1. DOI: 10.1053/j.gastro.2018.01.064.
[55] Dǎnilǎ M, Sporea I. Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis.an overview[J]. Med Ultrason, 2014, 16(2): 139-144. DOI: 10.11152/mu.201.3.2066.162.md1is2.
[56] Simmons O, Fetzer DT, Yokov T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2017, 45(1): 169-177. DOI: 10.1111/apt.13841.
[57] Kim SY, An J, Lim YS, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma[J]. JAMA Oncol, 2017, 3(4): 456-463. DOI: 10.1001/jamaoncol.2016.3147.
[58] Kim TH, Yoon JH, Lee JM. Emerging role of hepatobiliary magnetic resonance contrast media and contrast-enhanced ultrasound for noninvasive diagnosis of hepatocellular carcinoma: emphasis on recent updates in major guidelines[J]. Korean J Radiol, 2019, 20(6): 863-879. DOI: 10.3348/kjr.2018.0450.
[59] Renzulli M, Biselli M, Brocchi S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm[J]. Gut, 2018, 67(9): 1674-1682. DOI: 10.1136/gutjnl-2017-315384.
[60] Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J]. Liver Int, 2019, 39(12): 2214-2229. DOI: 10.1111/liv.14223.
[61] Yi XY, Yu S, Bao YX. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis[J]. Clin Chim Acta, 2013, 425: 212-220. DOI: 10.1016/j.cca.2013.08.005.
[62] Xing H, Zheng YJ, Han J, et al. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: a systematic review with meta-analysis[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(6): 487-495. DOI: 10.1016/j.hbpd.2018.09.009.
[63] Ji J, Wang H, Li Y, et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multicentre study[J]. PLoS One, 2016, 11(4): e0153227. DOI: 10.1371/journal. pone.0153227.
[64] Schotten C, Ostertag B, Sowa JP, et al. GALAD score detects early-stage hepatocellular carcinoma in a European cohort of chronic hepatitis B and C patients[J]. Pharmaceuticals(Basel), 2021, 14(8): 735. DOI: 10.3390/ph14080735.
[65] Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol, 2017, 14(9): 531-548. DOI: 10.1038/nrclinonc.2017.14.
[66] Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4): 223-238. DOI: 10.1038/nrc.2017.7.
[67] Wang SY, Zhang CX, Wang GZ, et al. Aptamer-mediated transparent-biocompatible nanostructured surfaces for hepotocellular circulating tumor cells enrichment[J]. Theranostics, 2016, 6(11): 1877-1886. DOI: 10.7150/thno.15284.
[68] Mong J, Tan MH. Size-based enrichment technologies for non-cancerous tumor-derived cells in blood[J]. Trends Biotechnol, 2018, 36(5): 511-522. DOI: 10.1016/j.tibtech.2018.02.010.
[69] Yang JD, Liu MC, Kisiel JB. Circulating tumor DNA and hepatocellular carcinoma[J]. Semin Liver Dis, 2019, 39(4): 452-462. DOI: 10.1055/s-0039-1688503.
[70] Tao KS, Bian ZY, Zhang Q, et al. Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma[J]. EBioMedicine, 2020, 56: 102811. DOI: 10.1016/j.ebiom.2020.102811.
[71] Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014, 6(224): 224ra24. DOI: 10.1126/scitranslmed.3007094.
[72] 王洋, 边振远, 尹纯, 等. 血液游离DNA检测肝癌的临床应用研究进展[J]. 中华肝胆外科杂志, 2018, 24 (5): 348-351. DOI: 10.3760/cma.j.issn.1007-8118.2018.05.017.
[73] Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11): 1155-1161. DOI: 10.1038/nmat4997.
[74] Qu CF, Wang YT, Wang P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy[J]. Proc Natl Acad Sci USA, 2019, 116(13): 6308-6312. DOI: 10.1073/pnas.1819799116.
[75] 早期肝癌“害怕”的研究数据[Z]. https: //wap.peopleapp.com/article/rmh19499839/0.
[76] 何佳, 肖斌, 孙朝晖. 血清微小RNA在肝癌诊断的应用进展[J]. 中华检验医学杂志, 2017, 40 (1): 72-76. DOI: 10.3760/cma.j.issn.1009-9158.2017.01.016.
[77] Cong M, Ou XJ, Huang J, et al. A predictive model using N-glycan biosignatures for clinical diagnosis of early hepatocellular carcinoma related to hepatitis B virus[J]. Omics, 2020, 24(7): 415-423. DOI: 10.1089/omi.2020.0055.
[78] Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients[J]. Radiology, 2018, 289: 816-830. DOI: 10.1148/radiol.2018181494.
[79] Wong GLH, Chan HLY, Wong CKY, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B[J]. J Hepatol, 2014, 60(2): 339-345. DOI: 10.1016/j.jhep.2013.09.029.
[80] World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis[Z]. https: //apps.who.int/iris/handle/10665/42699.
[81] Nguyen ALT, Nguyen HTT, Yee KC, et al. A systematic review and narrative synthesis of health economic evaluations of hepatocellular carcinoma screening strategies[J]. Value Health, 2021, 24(5): 733-743. DOI: 10.1016/j.jval. 2020.11.014.
[82] Qian MYY, Yuwei JR, Angus P, et al. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital[J]. J Gastroenterol Hepatol, 2010, 25(5): 951-956. DOI: 10.1111/j.1440-1746.2009.06203.x.
[83] Chang Y, Lairson DR, Chan W, et al. Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk[J]. J Eval Clin Pract, 2011, 17(2): 261-267. DOI: 10.1111/j.1365-2753.2010.01432.x.
[84] Kim HL, An J, Park JA, et al. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis[J]. Hepatology, 2019, 69(4): 1599-1613. DOI: 10.1002/hep.30330.
[85] 陈琪萍, 林苏, 史震山, 等. 钆塞酸二钠增强磁共振成像与超声在肝细胞癌筛查中的成本效益分析[J]. 临床肝胆病杂志, 2018, 34(9): 1917-1920. DOI: 10.3969/j.issn.1001-5256.2018.09.018.
[86] Andersson KL, Salomon JA, Goldie SJ, et al. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2008, 6(12): 1418-1424. DOI: 10.1016/j.cgh.2008.08.005.
[87] Lin OS, Keeffe EB, Sanders GD, et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C[J]. Aliment Pharmacol Ther, 2004, 19(11): 1159-1172. DOI: 10.1111/j.1365-2036.2004.01963.x.
[88] Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2.